Log In
Print this Print this

dasotraline (SEP-225289)

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionDopamine and norepinephrine reuptake inhibitor (DNRI)
Molecular Target Dopamine receptor ; Norepinephrine transporter
Mechanism of ActionDopamine and norepinephrine reuptake inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat ADHD; Treat ADHD in patients ages 6-12
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today